Eli Lilly has reached a procurement agreement with the EU to supply 220,00 doses of the US-based pharmaceutical company's antibody treatment for patients with Covid-19.
The Covid-19 treatment is a combination of two antibodies –bamlanivimab and etesevimab – which has shown itself to be effective in reducing the risk of hospitalization or death for people infected with Covid-19.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.